medifoxamine

Medifoxamine is a small molecule atypical antidepressant that was marketed in France, Spain, and Morocco in the 1990s for the treatment of unipolar depression. It also exhibited anxiolytic properties. The drug acts primarily as a relatively weak dopamine reuptake inhibitor and an even weaker serotonin reuptake inhibitor. Additionally, it functions as a weak antagonist at the serotonin 5-HT2A and 5-HT2C receptors. Medifoxamine undergoes extensive first-pass metabolism in the liver to produce active metabolites with greater pharmacological activity than the parent compound. Due to cases of hepatotoxicity reported during its use, medifoxamine was withdrawn from all markets[1][3][4][7].

Brand names

ClédialGerdaxyl

Other names

MedifoxaminaN,N-Dimethyl-2,2-diphenoxyethanamine32359-34-5